Immune Tolerance Network

AAN: Statin Therapy May Slow MS Progression

itn_admin — Fri, 16 Apr 2010 14:23:48 -0700

TORONTO -- The risk of developing new brain lesions was reduced by about 50% if patients with early forms of multiple sclerosis were taking atorvastatin (Lipitor), researchers said here at the annual meeting of the American Academy of Neurology.

The results are from an 18-month study designed to see whether statin therapy could slow the progression of multiple sclerosis.

Revealing the mechanisms of tolerance

itn_admin — Tue, 06 Apr 2010 14:48:51 -0700

Inducing remission in ANCApositive vasculitis: time to RAVE?

itn_admin — Tue, 30 Mar 2010 14:19:25 -0700

Standard therapy for vasculitis associated with antineutrophil
cytoplasmic antibodies can achieve high rates of remission, but with the
risk of serious toxic effects. the results of a placebo-controlled trial in
patients with severe disease suggest that an effective alternative could
be on the horizon.

Can Peanut Allergies Be Cured by ... Eating Peanuts?

itn_admin — Fri, 05 Mar 2010 16:39:04 -0800

In 2008, Gideon Lack of King's College London published a startling study comparing the rate of peanut allergies in children in London with that of children in Tel Aviv. The study of 10,000 Jewish children, which appeared in the Journal of Allergy and Clinical Immunology, found that kids in the U.K. were almost 10 times as likely to have a peanut allergy as their peers in Israel, says Lack.

Rebooting the body

itn_admin — Fri, 26 Feb 2010 08:16:43 -0800

Researchers Discover Potential Diabetes Cure

itn_admin — Fri, 24 Oct 2008 00:00:00 -0700

Fighting Peanut Allergies With Peanuts

itn_admin — Thu, 23 Oct 2008 00:00:00 -0700

New Research and New Approaches Offer Hope to Families Coping With Food Allergies

By LISA STARK

Three-year-old Peyton Youse of Charlotte, N.C., is severely allergic to peanuts.

But now doctors are fighting back -- with peanuts.

Rho brings multi-million dollar federal contract to RTP

itn_admin — Thu, 04 Sep 2008 00:00:00 -0700

Research Triangle Park, N.C. — Rho, Inc., a scientific/medical contract research organization that serves the biotechnology and pharmaceutical industries and the National Institutes of Health (NIH), has been awarded a six-year, $38.9 million contract through the National Institute of Allergy and Infectious Diseases (NIAID) to provide biostatistical, data management, and safety services to the Immune Tolerance Network (ITN).

86 Years After Insulin, Type I Diabetes Drugs Promise More

itn_admin — Mon, 25 Aug 2008 00:00:00 -0700

Original article at BioWorld Today

By Karen Pihl-Carey

Senior Staff Writer, BioWorld Today

In the early part of the 20th century, before the Depression and World War II, dozens of children lay comatose in hospital wards where hopeless families gathered awaiting their inevitable deaths.

A successful mixture: Transplanting immune-system stem cells along with kidneys stops rejection

itn_admin — Mon, 04 Aug 2008 15:12:00 -0700

In Diabetic Mice, Antibody Therapy Activates Disease-Controlling, Regulatory T Cells

itn_admin — Thu, 29 May 2008 22:00:00 -0700

Breakthrough spares kidney transplant patients

itn_admin — Thu, 24 Jan 2008 00:00:00 -0800

LOS ANGELES -- In what's being called a major advance in organ transplants, doctors say they have developed a technique that could free many patients from having to take anti-rejection drugs for the rest of their lives.

The treatment involved weakening the patient's immune system, then giving the recipient bone marrow from the person who donated the organ. In one experiment, four of five kidney recipients were off immune-suppressing medicines up to five years later.

Doctors report transplant breakthrough

itn_admin — Thu, 24 Jan 2008 00:00:00 -0800

by Alicia Chang, 24 January 2008

LOS ANGELES (AP) - In what's being called a major advance in organ transplants, doctors say they have developed a technique that could free many patients from having to take anti-rejection drugs for the rest of their lives.

Scientist triumphs after setback in kidney transplant method

itn_admin — Wed, 23 Jan 2008 00:00:00 -0800

Dr. David H. Sachs was full of optimism when the third patient in his $1 million study was wheeled into the recovery room at Massachusetts General Hospital after an experimental kidney transplant.

The first two patients had thrived, adding credibility to an unorthodox idea that Sachs had pioneered over his career, that transplanting a donor's bone marrow along with the kidney could solve the problem of organ rejection, sparing patients a lifetime of powerful antirejection drugs.

Study: Transplant Patients Stop Rejection Drugs

itn_admin — Wed, 23 Jan 2008 00:00:00 -0800

All Things Considered, January 23, 2008 · Organ transplants have saved thousands of lives over the past 50 years. But to prevent rejection of transplanted organs, patients have to take toxic drugs for the rest of their lives.

Now, several new studies show that it's possible for some transplant patients to avoid these drugs and their side effects. The studies appear in this week's New England Journal of Medicine.

One of the first transplant patients who volunteered to stop taking anti-rejection drugs was Jennifer Serle.